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ABSTRACT G-protein-coupled receptors (GPCRs) are known to exist in dynamic equilibrium between inactive- and several
active-state conformations, even in the absence of a ligand. Recent experimental studies on the b2 adrenergic receptor (b2AR)
indicate that structurally different ligands with varying efﬁcacies trigger distinct conformational changes and stabilize different
receptor conformations. We have developed a computational method to study the ligand-induced rotational orientation changes
in the transmembrane helices of GPCRs. This method involves a systematic spanning of the rotational orientation of the
transmembrane helices (TMs) that are in the vicinity of the ligand for predicting the helical rotations that occur on ligand binding.
The predicted ligand-stabilized receptor conformations are characterized by a simultaneous lowering of the ligand binding
energy and a signiﬁcant gain in interhelical and receptor-ligand hydrogen bonds. Using the b2AR as a model, we show that the
receptor conformational state depends on the structure and efﬁcacy of the ligand for a given signaling pathway. We have
studied the ligand-stabilized receptor conformations of ﬁve different ligands, a full agonist, norepinephrine; a partial agonist,
salbutamol; a weak partial agonist, dopamine; a very weak agonist, catechol; and an inverse agonist, ICI-115881. The predicted
ligand-stabilized receptor models correlate well with the experimentally observed conformational switches in b2AR, namely, the
breaking of the ionic lock between R1313.50 at the intracellular end of TM3 (part of the DRY motif) and E2686.30 on TM6, and the
rotamer toggle switch on W2866.48 on TM6. In agreement with trp-bimane quenching experiments, we found that norepineph-
rine and dopamine break the ionic lock and engage the rotamer toggle switch, whereas salbutamol, a noncatechol partial
agonist only breaks the ionic lock, and the weak agonist catechol only engages the rotamer toggle switch. Norepinephrine and
dopamine occupy the same binding region, between TM3, TM5, and TM6, whereas the binding site of salbutamol is shifted
toward TM4. Catechol binds deeper into the protein cavity compared to the other ligands, making contact with TM5 and TM6. A
part of the catechol binding site overlaps with those of dopamine and norepinephrine but not with that of salbutamol. Virtual
ligand screening on 10,060 ligands on the norepinephrine-stabilized receptor conformation shows an enrichment of 38%
compared to ligand unbound receptor conformation. These results show that ligand-induced conformational changes are
important for developing functionally speciﬁc drugs that will stabilize a particular receptor conformation. These studies represent
the ﬁrst step toward a more universally applicable computational method for studying ligand efﬁcacy and GPCR activation.
INTRODUCTION
Ligands for G-protein-coupled receptors (GPCRs) vary in
size from small molecules to proteins, and they elicit varied
responses in GPCR-mediated cell signaling pathways. There
is substantial evidence that GPCRs exist in multiple inactive
and active conformational states that are in dynamic equi-
librium (1–3). GPCR ligands exhibit different types and
ranges of efﬁcacies depending on the receptor and the sig-
naling pathway it activates. Thus, we have
1. Full agonists that bind and activate a particular signaling
pathway in the receptor.
2. Partial agonists that bind and activate the receptor to
different degrees, typically less than that of the full agonist.
3. Neutral antagonists that bind but prevent activation of the
receptor (these ligands, however, do not alter the consti-
tutive activity of the receptor if any).
4. Inverse agonists that suppress the constitutive activity of
the receptor and therefore do not activate the receptor.
The relative efﬁcacies of the ligands should be compared
for their response to the same signaling pathway. Adrenergic
receptors (AR) constitute a very important subclass of GPCRs
and have been studied well for the effect of ligand structure
on receptor activation (4–17). Extensive site-directed muta-
tional studies on b2AR for the purposes of drug design
(18–21) point to the binding pocket of epinephrine, the en-
dogenous agonist, being in the transmembrane (TM) domain
deﬁned by helices 3, 4, 5, and 6. However it is not clear which
residues in the TM region lead to activation of the receptor.
There are several types of ligands known for b2AR. Epi-
nephrine and norepinephrine are full agonists for b2AR-
mediated GDP/GTP exchange in the G-protein, whereas
salbutamol and dopamine are partial agonists, and ICI-118551
is an inverse agonist that blunts the basal activity of b2AR.
These molecules are highly related in structure and yet elicit
very different responses for the same signaling pathway from
the receptor. Norepinephrine and salbutamol have high struc-
tural similarity, but with slightly different functional groups
and good binding afﬁnities to b2AR, but norepinephrine is an
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agonist whereas salbutamol is a partial agonist to the recep-
tor-mediated GDP/GTP exchange in the G-protein.
Using ﬂuorescence spectroscopic techniques on puriﬁed
b2AR protein, Kobilka and co-workers have shown that
GPCR activation is a multistep process and that ligands with
different chemical structures stabilize different receptor con-
formations (6,11). They have also studied the nature of con-
formational changes by probing into the interhelical contacts
that are broken on ligand binding and activation. By attaching
ﬂuorescent probes at different locations within b2AR,
Kobilka and co-workers showed that upon activation, nor-
epinephrine and dopamine both break the ionic lock between
R1313.50 at the intracellular end of TM3 (part of the DRY
motif) and E2686.30 on TM6, and turn on the rotamer toggle
switch on TM6, whereas salbutamol only engages the ionic
lock, and catechol (which is a weak partial agonist) engages
only the rotamer toggle switch (6,9–11). Here, we have used
the Ballesteros residue numbering system for GPCRs (22).
Swaminath et al. have shown that the aromatic ring of sal-
butamol occupies a different binding region than the aromatic
rings of catecholamine agonists such as dopamine and epi-
nephrine (11). Thus, there is a strong correlation between
ligand efﬁcacy and the stabilized conformational state.
However, the detailed characteristic features of the different
ligand-stabilized receptor conformations are still unknown.
Besides ﬂuorescence measurements, conformational changes
have been detected by measuring the solvent accessibilities
of mutated cysteines at different points in the receptor.
Javitch and co-workers (7) found a counterclockwise rota-
tion of TM6, viewing from the extracellular side. Other
studies have reported the importance of conserved aromatic
residues on TM6, such as F2826.44 (16). It was found that
mutating F2826.44 to a hydrophobic residue (Leu or Ala)
increased the constitutive and norepinephrine-induced activi-
ties of b2AR.
A variety of techniques, such as ﬂuorescence measure-
ments (12,23), site-directed mutagenesis (16,17,24), cysteine
accessibility (7,8,13), disulﬁde cross-linking (25,26), zinc
cross-linking (23), EPR spectroscopy (26), spin labeling
(27–29), circular dichroism (23), and x-ray crystallography
(30), have been used to investigate the activation mechanism
in GPCRs. Since bovine rhodopsin is the only GPCR whose
crystal structure is available, the initial attempts in studying
the activation process were mainly targeted toward rhodopsin
(2,23,26–32). Using site-directed spin labeling (SDSL) and
cysteine cross-linking measurements, Khorana and co-
workers showed that the activation of rhodopsin involves a
relative motion of TM6 with respect to TM3. The SDSL
results indicated a counterclockwise rotation of TM6 when
viewed from the extracellular side. Also, cross-linking the
cysteine residues at the cytoplasmic ends of TM3 and TM6
prevented transducin activation, which showed that the in-
tracellular ends of TM3 and TM6 move away from one
another on activation (26). The role of the highly conserved
DRY motif in rhodopsin activation was highlighted by Arnis
et al. (33), who showed that charge-neutralizing mutations
of the arginine D(E)RY increased the constitutive activity of
rhodopsin. This result was later interpreted as the breaking
of the ionic lock when the high-resolution crystal structure of
inactive rhodopsin became available. Crystal structures of
several photointermediates of rhodopsin have been reported
recently (34,35), which allows us to observe their differences
from the dark state of rhodopsin. In the crystal structure of
metarhodopsin II, W2656.48 on TM6 was found to toggle its
rotamer, showing evidence of a universal switching mecha-
nism for GPCR activation (23,26). Recent modeling studies
have used constrained molecular dynamics (MD) and con-
formational scanning techniques to develop structural models
of active GPCRs such as rhodopsin and b2AR (36,37).
Although an atomic-resolution structure of the active state of
rhodopsin (or any other GPCR) is still not known, detailed
experimental information is available for multiple ligands
of varied efﬁcacy, and their corresponding receptor confor-
mations for b2AR thereby offer a good model system for
studying GPCRs.
For better drug design, it is necessary to identify the dif-
ferent receptor conformations that are stabilized by various
ligands (38,39). Computational methods in mapping the
conformational changes in the receptor on ligand-binding are
relatively few, mainly due to the long timescale of the con-
formational changes. MD simulation techniques have been
used to observe short-timescale, initial events of activation
in GPCRs (40–42). However, MD simulation timescales are
still insufﬁcient to simulate large-scale motions.
In this article, we have developed a computational method
that involves systematic spanning of the conformational
subspace of the TM helices in GPCRs, combined with energy
minimization, to predict the conformational changes that
occur on ligand binding. We call this method ligand-induced
transmembrane rotational conformational changes (LITiCon),
and it optimizes the ligand-stabilized receptor conformations
for ligands with different efﬁcacies. This method provides a
model to predict the interhelical contacts made or broken in
the vicinity of ligand binding, which is useful in designing
residues to label for ﬂuorescent experiments that delineate
the conformational switches leading to the activation of
GPCRs. We have validated LITiCon for b2AR by predicting
the receptor conformations that are stabilized by norepi-
nephrine (a full agonist), salbutamol (a noncatechol partial
agonist), and dopamine (a partial agonist), and catechol (a
very weak partial agonist). The structures of these com-
pounds are shown in Fig. 1.
We have correlated the residue distances in the predicted
ligand-stabilized receptor models with the available ﬂuores-
cence or Trp-bimane ﬂuorescence quenching experiments for
b2AR (6,9–11). In the predicted structural models, we ob-
serve that norepinephrine and dopamine break the ionic lock
and rotamer toggle switch, whereas salbutamol and catechol
engage one of them but not both, as observed in experiments.
Analysis of the binding sites reveals distinct similarities and
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differences in the residues present in the ligand-binding site
that bring out the salient features of ligand-stabilized recep-
tor conformations. For example, norepinephrine shows an
equally strong interaction with both S2035.42 and S2045.43 on
TM5, whereas salbutamol shows a preferentially stronger
interaction with S2045.43. These salient differences among
the binding modes of the various ligands will help us to
distinguish strong agonists from weak and partial agonists.
We also ﬁnd that the interhelical contact between F2826.44 on
TM6 and Y3267.53 on TM7 breaks on binding of norepi-
nephrine, but not on that of salbutamol. On binding of nor-
epinephrine, an interhelical hydrogen bond (HB) is formed
between M2155.54 on TM5 and W2866.48 on TM6 which is
absent for dopamine binding. This would allow us to dis-
tinguish norepinephrine-bound b2AR from the dopamine-
bound conformation of b2AR. Finally, we discuss how the
ligand-perturbed receptor model shows better discrimination
for adrenergic ligands, and these models could be used in
virtual ligand screening (VLS) for drug design in GPCRs.
COMPUTATIONAL METHODS
LITiCon
We have developed a computational procedure to map the perturbations in
the helical rotational orientations induced by ligand binding in the TM region
of GPCRs. This method consists of two steps.
1. We identify which of the TM helices get perturbed directly on ligand
binding.
2. Once the helices have been identiﬁed, there is a systematic and simul-
taneous spanning of orientations on all the TMs involved in ligand bind-
ing. For each combination of the rotational orientations several properties
are calculated as described below. This step generates the binding energy
surface of the entire rotational space of the helices between the initial
(ligand not bound) and ﬁnal states. This energy surface will be used to
identify the ﬁnal ligand-stabilized conformational changes that the receptor
undergoes and possibly the trajectory of the receptor conformational
changes from the initial state to the ﬁnal state.
The computational method described below is applicable to any starting
structure or structural model of a GPCR. For example, one could start from
the crystal structure, or the model of a GPCR generated by homology
modeling techniques, or any other predicted model.
Step 1: ligand-bound rotational optimization
In this step, individual TM helices are rotated from 180 to 180 in in-
crements of 5. Details of the rotations and the rotational axes are provided in
Supplementary Material. The following four steps are performed for each
conformation generated:
1. Optimization of all side-chain conformations using SCWRL 3.0 (43).
2. Conjugate gradient minimization of the potential energy of the rotated
TM region in the ﬁeld of the rest of protein ﬁxed until convergence of
0.1 kcal/mol-A˚ RMS deviation in force/atom is achieved.
3. Minimization of the entire protein for 1000 steps or until RMS in force/
atom is 0.1 kcal/mol-A˚.
4. At each of these rotational steps we also calculate
a. the ligand binding energy, deﬁned as the difference of the potential
energy of the ligand with protein ﬁxed, and the potential energy of
the free ligand with generalized Born solvation method (44).
b. interhelical and ligand-receptor hydrogen bonds using HBPLUS 3.0
(45); and
c. interhelical salt bridges.
This produces a map of the ligand-binding energies, along with other
calculated properties for all the rotational conformations from 0 to 360
rotations for each TM helix. The change in binding energy and the inter-
helical hydrogen bonds plus the ligand-receptor hydrogen bonds are plotted
as shown in Fig. 2. This would lead to identiﬁcation of the TM helices that
undergo conformational changes on ligand binding. For example, Fig. 2
shows the rotational angle optimization for TM3, TM5, and TM6, demon-
strating the signiﬁcant change in binding energies for norepinephrine bound
to b2AR.
Step 2: calculation of the binding energy surface
for systematic conformational subspace
sampling of simultaneous rotational orientation
of all the TM helices
The results of step 1 showwhich of the helices undergo helical rotations upon
direct contact with the ligand. In this step, we perform simultaneous rotations
of all the helices directly impacted by ligand binding, from180 to 180 in
steps of 5. For example, in the case of norepinephrine-bound b2AR, si-
multaneous rotations of helices 3, 5, and 6 would be performed. This pro-
cedure ensures a systematic spanning of all combinations of rotational
orientations of all the helices involved directly in ligand binding. Such an
optimization procedure would allow us to go over barriers that MD simu-
lations cannot overcome. Each rotational combinatorial conformation thus
generated is subject to the four steps of calculation described above in step
1 of the LITiCon procedure. Since more than one TM helix is being rotated
simultaneously, all the TM helices that get rotated are allowed to move
during the conjugate gradient energy minimization in step 3. For each gen-
erated conformation, we calculate the binding energy of the ligand, the
FIGURE 1 Structures of b2AR ligands used in this study.
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number of protein-ligand HBs, and the number of interhelical HBs (see
Supplementary Material for a description of the methods used for identifying
minima) and sort them by total number of hydrogen bonds and then by
binding energy. The ﬁnal ligand-stabilized receptor structure is selected
based on low binding energy and high number of hydrogen bonds.
MD simulations of the ligand-stabilized receptor
conformations
The two steps of the LITiCon method do not take into account the allosteric
conformational changes in the TM regions that do not contact the ligand
directly, or the conformational changes in the TM regions due to hinge
bending and tilting of the helices and also the conformational changes in the
loop regions that occur on ligand binding. To account for such conforma-
tional changes, MD simulations of the predicted ligand-stabilized receptor
conformations are performed in an explicit lipid bilayer, water, and salt. We
use the NAMD (46) MD simulation package for this purpose. The bilayer
was constructed out of palmitoyloleoyl phosphatidylcholine lipid mole-
cules packed around the TM barrel of the receptor. The total number of
atoms in the system was ;80,000. The CHARMM22 force ﬁeld was used
to model the interatomic interactions. A 15-ns NVT constant-temperature
MD simulation was performed at 310 K (human body temperature) on the
norepinephrine-bound b2AR and the apoprotein.
In this study, we applied the LITiCon method on b2AR bound to the
agonists norepinephrine, salbutamol, dopamine, and catechol, as well as
the inverse agonist ICI-118551. The helical rotational changes induced in the
TM region on ligand binding are analyzed. The ligand-docked conformations
of b2AR for each of the ligands was then used to pack a double layer of the
lipid palmitoyloleoyl phosphatidylcholine around the ligand-docked protein
structures using rigid-body molecular dynamics (47). Subsequently we
performed steps 1–3 of the LITiCon procedure as described in detail previ-
ously in this section.
Calculation of the strength of the ionic lock between
TM3 and TM6
We have calculated the strength of interaction between R1313.50 and
E2686.30 using the following procedure. For each ligand-stabilized model
of the receptor from LITiCon, we performed side-chain rotamer reassign-
ment for residues R1313.50 and E2686.30 with and without the constraints
of making this ionic lock using the side-chain reassignment program
SCREAM (V. Kam and W. A. Goddard 3rd, unpublished). The best energy
structure for the conformation with the ionic lock was compared to the
best energy structure of the conformation without the ionic lock. The en-
ergy calculated is the potential energy computed with the CHARMM22
force ﬁeld.
FIGURE 2 (a) Plot of change in ligand-binding energy for various rotation angles of helices 3, 5, and 6 with norepinephrine bound. (b) Plot of interhelical
hydrogen bonds. (c) Ligand receptor hydrogen bonds.
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Ligand docking methods
We have used the MembStruk4.0 method (49) to predict the structural model
of human b2AR as the starting structure for LITiCon. We have predicted an
ensemble of structural models for the apoprotein of human b2AR. The in-
dividual ligands shown in Fig. 1 were docked to the apoprotein model using
the hierarchical docking procedure described in this section.We have docked
ligands with various afﬁnities and efﬁcacies to the ensemble of receptor
conformations of b2AR. We have used a DREIDING force ﬁeld for the re-
ceptor and ligand and CHARMM22 charges for the protein. The ligands
were built with the Maestro suite of software (Schrodinger, Portland, OR)
and the quantum-mechanical ESP ﬁtted charges were calculated in a solvent
of low dielectric since this would mimic the interior of the GPCR TM barrel.
The ScanBindSite algorithm (50,51) was performed individually for each
ligand to scan the entire receptor surface and locate possible binding re-
gion(s).
We then performed ligand conformational sampling using the Monte
Carlo sampling program in the Macromodel suite in Maestro. Each low-
energy ligand conformation was docked into the putative binding site using
Glide extraprecision docking (52). We kept 500 docked conformations for
each ligand from Glide and sorted them by buried surface area of the ligand
and interaction energy with the protein. The top 100 ligand docked confor-
mations were minimized with protein ﬁxed and the binding energies were
calculated as the difference between the ligand energy in protein and the
ligand energy in water. The ligand energy in water was calculated using
the generalized Born module in Maestro. The ﬁnal docked structures for all
the ligands were also subjected to the induced-ﬁt docking model from the
Prime module in Maestro. In induced-ﬁt docking, the side chains of all
residues inside the binding pocket were made ﬂexible for efﬁcient sampling
of the docked conformations. This ensured that the ligand-induced shape
ﬂuctuations of the binding pocket were taken into consideration during
prediction of the docked structures.
Method used for virtual ligand screening of
optimized receptor conformations
Virtual ligand screening is a stringent test of the usefulness of the ligand-
stabilized receptor models for selecting speciﬁc drugs. The 10,000-ligand
test set was picked randomly from 300,000 compounds in the National
Cancer Institute database. Next, 60 known adrenergic ligands were added to
the 10,000 compounds to create the ﬁnal test set of 10,060 compounds. The
set of adrenergic ligands is diverse enough to include antagonists, inverse
agonists, full and partial agonists, and noncatechol compounds. These
compounds were then docked to the receptor models using the HTVS mode
of GLIDE. Both the receptor and the ligand vdW radii were scaled down by
50% to allow soft receptor conformations. The docked conformations were
ﬁrst sorted by total charge and then by protein-ligand interaction (sum of
vdW and HB interaction). The percentage yield of adrenergic ligands for
cutoff c is deﬁned as
%Yield ¼ Number of adrenergic ligands at cutoff c
Total number of adrenergic ligands in the test set
:
Therefore, the yield represents the relative probability of selecting adrenergic
ligands at a certain cutoff after ﬁltering compared to randomly selecting
ligands from the test set.
RESULTS AND DISCUSSION
Predicted apoprotein model
In the initial predicted structural model, the key conserved
residues such as N511.50 on TM1, D792.50 on TM2, and
N3227.49 on TM7 (part of the NPxxY motif) are all facing the
protein core. These residues form a HB network in the pre-
dicted model, which is also observed in the crystal structure
of rhodopsin. R1313.50 at the intracellular end of TM3 (part of
the DRY motif) forms a salt bridge with E2686.30 on TM6
(the ionic lock). Using the ScanBindSite algorithm, we pre-
dicted the binding cavity for all the ligands studied here to be
between TM3, TM5, and TM6, which is in agreement with
published mutation studies (18,53,54). The key residues in-
volved in ligand binding are all facing the binding cavity.
These are D1133.32 on TM3, N2936.55 and the WxP motif on
TM6. Among the serines on TM5 that are involved in
binding, S2035.42 and S2075.46 are inside the binding cavity,
and S2045.43 is outside, facing the membrane. Later in this
work, we show that after optimizing the receptor conforma-
tions in the presence of the ligands, all three serines come
inside the binding cavity, making contact with the ligands.
Perturbation of the ligand-binding site and the
TM helices after ligand binding
The ligand-docked structural models of b2AR for each of the
ﬁve ligands studied here were all subjected to the LITiCon
procedure. The ﬁrst step of the LITiCon procedure, to deci-
pher which TM helices are affected by ligand binding,
showed that helices 3, 5, and 6 undergo conformational
changes (on ligand binding) for all the ﬁve ligands. This is
demonstrated in Fig. 2 for norepinephrine. For example, it is
seen from Fig. 2 a that TM3 shows preferences for speciﬁc
receptor conformations around 45 to 45 rotations. The
other four TM helices (TM1, TM2, TM4, and TM7) did not
show any change in binding energy. In addition to TM3,
TM5, and TM6, TM7 also shows a change in binding energy
on rotation, for norepinephrine, salbutamol, and ICI-118551
(Supplementary Material, Fig S3). However, the preferred
receptor conformation for TM7 is the starting conformation
and therefore TM7 rotations were not considered for step 2 of
the LITiCon procedure. The computations involved in si-
multaneous rotations of TM helices 3, 5, and 6 for all the ﬁve
ligands were performed and the binding potential energy
surfaces were calculated for various rotational orientations of
TM3, TM5, and TM6. This is a four-dimensional surface,
and the best ligand optimized receptor conformation was
chosen after sorting the various minima in this binding en-
ergy surface by interhelical hydrogen bonds, ligand-receptor
hydrogen bonds, and ligand binding energy.
Conformational switches triggered by ligand
binding and correlation to experiments
The best ligand-stabilized receptor model for each ligand was
validated by qualitative comparison (quantitative distances
are not available from experiments) of the residue distances
to those obtained from Trp-bimane quenching, FRET, and
cysteine accessibility experiments in b2AR. Fig. 3 shows
snapshots of the predicted conformations before and after the
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ligands norepinephrine and salbutamol bind to b2AR. The
ionic lock between R1313.50 and E2686.30 is disrupted (dis-
tance over 10A˚) in all norepinephrine-, dopamine-, and sal-
butamol-stabilized receptor models. For brevity, only the
norepinephrine-bound conformation is shown in Fig. 3 b.
Fig. 3 also shows the change in the rotamer ofW2866.48 on
TM6 upon norepinephrine binding, which represents the
rotamer toggle switch. In the apoprotein structure (Fig. 3 c),
the nitrogen of W2866.48 is facing the protein core toward
TM2, similar to the rhodopsin crystal conformation. In the
crystal structure of inactive rhodopsin, the nitrogen of the
conserved tryptophan on TM6 forms a water-mediated hy-
drogen bond with a conserved aspartate on TM2. During the
MD simulations of the b2AR apoprotein structure, water
moved into the binding cavity and formed a hydrogen-bond
network connecting residues W2866.48 and D792.50. Fig. 3 c
shows the apoprotein structure after 15 ns of MD simulation,
along with the positions of the two water molecules that take
part in the water-mediated hydrogen bond. In all the struc-
tures shown in Fig. 3, the atomic positions are averaged over
a period of the last 1 ns. In the norepinephrine-bound struc-
ture shown in Fig. 3 d, W2866.48 switches to a different ro-
tamer that places the nitrogen atom of W2866.48 away from
the protein core and facing TM5. However, in the salbutamol
and ICI-118551 bound structures, the rotamer conformations
of W2866.48 are the same as in apoprotein. We have deter-
mined the preferred orientation of W2866.48 rotamer in each
of the ligand-bound conformations (Supplementary Material,
Fig. S5) and found that norepinephrine, dopamine, and cat-
echol engage the rotamer toggle switch, whereas salbutamol
and ICI-118551 do not. This is in agreement with a previ-
ously reported rotamer toggle switch for these ligands (6).
TM helical rotations in b2AR with
norepinephrine bound
Fig. 4 shows the binding site of norepinephrine in the ligand
optimized conformation. In the apoprotein model, the pro-
tonated amine nitrogen of norepinephrine forms a salt bridge
with D1133.32 on TM3 (a distance of 2.87 A˚) and the b-OH
forms a HB with N2936.55 on TM6 (a distance of 2.88 A˚).
These contacts are preserved in the ligand-stabilized con-
formation as well. From site-directed mutagenesis studies,
mutations of D1133.32 to Asn (18) and N2936.55 to Leu (55)
reduce the binding afﬁnity of full agonists by 8000- and 36-
fold, respectively. Also, experimentally, mutations of all the
three serines, Ser-2035.42 (24), Ser-2045.43, and Ser-2075.46
(54) on TM5 have been shown to reduce the binding afﬁnity
of norepinephrine by 25, 33, and 39 times, respectively. In
the ligand-stabilized model, the two serines, S2045.43 and
S2075.46, move into the binding pocket. Both S2035.42 and
S2045.43 form HBs with the catechol para OH (4.5 A˚
and 4 A˚), whereas S2075.46 forms a HB with the meta OH
FIGURE 3 Conformational switches in human b2AR. (a) Ionic lock in
apoprotein. (b) Breaking of ionic lock by norepinephrine. (c) W2866.48
rotamer in the apoprotein conformation. The water mediated hydrogen bond
between W2866.48 and D792.50 is highlighted. (d) Toggling of the W2866.48
rotamer by norepinephrine. (e) No change in the W2866.48 rotamer for the
salbutamol-bound conformation (not toggled).
FIGURE 4 Predicted binding site in the norepinephrine optimized b2AR
conformation. The residues within 5 A˚ of the ligand are shown in gray. The
residues having strong interaction with the ligand are in green.
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(2.9 A˚). Besides the experimentally veriﬁed residues, we
observe that F2085.47 on TM5 and W1093.28 on TM3 move
closer to norepinephrine (,7 A˚) in the ligand-stabilized re-
ceptor conformation. The ligand optimized model is also
characterized by the disruption of several interhelical HBs, as
well as the formation of new ones. The HB between N3227.49
on TM7 and D792.50 on TM2 is preserved in both the apo-
protein and the ligand optimized models. However, the HB
between N3187.45 on TM7 and C2856.47 on TM6 is broken in
the ligand optimized model. A new HB is formed between
W2866.48 on TM6 and M2155.54 on TM5. The toggled ro-
tamer of W2866.48 results in the formation of a HB with
M2155.54, thereby stabilizing this rotamer in the norepi-
nephrine optimized model.
TM helical rotations in b2AR with
dopamine bound
Fig. 5 shows the binding site in the ligand optimized receptor
model for dopamine. TM3 shows a helical rotation similar to
that of norepinephrine, whereas TM5 and TM6 show slightly
different rotational orientations. Dopamine-bound b2AR
shows a TM5 rotation that is 10 higher than for norepi-
nephrine. D1133.32 on TM3 makes a salt-bridge contact
(distance of 2.9 A˚) with the protonated primary amine group
of dopamine. Unlike the norepinephrine-stabilized state of
b2AR, the dopamine-stabilized model of b2AR shows a HB
between S2045.43 and S2075.46 and catechol hydroxyl groups
(distances between heavy atoms of 5.2 A˚ and 2.9 A˚, re-
spectively). S2035.42 has no HB with dopamine (distance 6.4
A˚). This is in agreement with site-directed mutagenesis re-
sults for dopamine that show that the S204C mutation has a
stronger effect (a sevenfold reduction in binding) compared
to S203C (a 2.5-fold reduction in binding) (54). TM6 shows a
preference for a smaller rotation angle in the dopamine-
bound conformation compared to the norepinephrine-bound
conformation, and this helical rotation still turns on the ro-
tamer toggle switch. The interhelical HB between W2866.48
and M2155.54 is not formed in the dopamine-bound confor-
mation, whereas this HB is formed in the norepinephrine-
bound conformation. Due to the smaller rotation of TM6, the
side chain of W2866.48 in the dopamine-bound structure is
not sufﬁciently close to M2155.54, as it is in the norepi-
nephrine-bound structure. Besides this, the HB between
N3187.45 and C2856.47 is preserved in the dopamine-bound
state, whereas this HB is broken in the norepinephrine-bound
state. These two interhelical HBs can be used to differentiate
the norepinephrine-bound state from the dopamine-bound
state. They can be tested experimentally to delineate the role
of the b-OH group in norepinephrine compared to that in
dopamine. Dopamine shows a smaller change in binding
energy after conformational changes to its optimized receptor
conformation compared to norepinephrine.
TM helical rotations in b2AR with catechol bound
Due to its smaller size, catechol buries deeper into the
binding pocket than norepinephrine, salbutamol, or dopa-
mine. Catechol induces almost the same helical rotation in
TM5 as the other three agonists. In the predicted model of the
catechol-stabilized receptor conformation (Fig. 6), all the
TM5 serines are inside the binding pocket. One of the -OH
groups of catechol forms a HB with S2075.46 on TM5 (HB
distance, 4.1 A˚). The other -OH group forms a HB with
N2936.55 on TM6 (HB distance, 3.9 A˚). Catechol induces a
much smaller rotation in TM3 compared to norepinephrine,
dopamine, or salbutamol. Unlike the other ligands, catechol
does not have a protonated amine group and hence does not
form any salt bridge with D1133.32 on TM3. Catechol shows
favorable interactions with several hydrophobic residues on
FIGURE 5 Predicted binding site in the dopamine optimized b2AR confor-
mation. The residues within 5 A˚ of the ligand are shown in gray. The residues
having strong interaction with the ligand are in green.
FIGURE 6 Predicted binding site in the catechol optimized b2AR con-
formation. The residues within 5 A˚ of the ligand are shown in gray. The
residues having strong interaction with the ligand are in green.
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TM3, such as V1143.33 and V1173.36. The rotation of TM3
results in optimizing the interactions of these residues with
catechol. Catechol interacts strongly with the aromatic resi-
dues on TM6, such as F2906.52 and W2866.48, and also with
N2936.55. Although TM6 shows no major backbone change
in the presence of catechol, the rotamer of W2866.48 is tog-
gled by catechol.
TM helical rotations in b2AR with
salbutamol bound
Salbutamol is a noncatechol strong partial agonist that is
structurally different compared to both norepinephrine and
dopamine. Fig. 7 shows the predicted binding site in the sal-
butamol-stabilized b2AR receptor conformation. Salbutamol
has a protonated secondary amine nitrogen with a tertiary
butyl group attached to it, and a b-OH group similar to nor-
epinephrine, and instead of two OH groups on the aromatic
ring, it has one OH group and another -CH2OH group. From
our calculations, all three TMs—TM3, TM5, and TM6—in
the salbutamol-bound structure show smaller rotations com-
pared to norepinephrine. TM3 rotates by a smaller angle, so
that W1093.28 makes a weaker contact with the ligand com-
pared to the norepinephrine-bound structure. D1133.32 makes
a strong salt-bridge contact with the protonated amine (dis-
tance, 2.9 A˚). Due to the long -CH2OH group of salbutamol, a
smaller rotation of TM5 places the serines in close proximity
to the hydroxyl groups of salbutamol compared to norepi-
nephrine. Unlike norepinephrine, N2936.55 does not form a
HB with the b-OH group of salbutamol. Instead the b-OH
group makes a HB with D1133.32. Mutation studies have
shown that unlike norepinephrine, the b-OH group in non-
catecholamine agonists does not interact strongly with
N2936.55 (55). Mutating N2936.55 to Leu reduced the binding
of the  isomer of norepinephrine 11-fold, whereas the re-
duction in binding was only fourfold for the 1 isomer.
Therefore, the characteristics of the predicted binding site
agree well with these mutation studies that bring out the
differences in the recognition of the stereoisomers. Due to
the presence of a bulky alkyl -(CH3)3 group at one end,
salbutamol also interacts with TM7, although there is no
signiﬁcant change in the rotational orientation observed in
the calculations presented here. L3117.38 shows favorable
van der Waals interaction with the alkyl group of salbutamol.
TM helical rotations in b2AR with
ICI-118551 bound
ICI-118551 is an inverse agonist to b2AR, which has been
shown to reduce the basal activity of wild-type b2AR. Fig. 8
shows the predicted binding site for ICI-118551 in the lig-
and-stabilized receptor conformation. According to our cal-
culations, the ICI-118551-bound structure shows rotations of
all three TMs (3, 5, and 6) and these rotations are smaller in
magnitude compared to the agonist-stabilized states, thereby
preserving the ionic lock between TM3 and TM6. The lig-
and-stabilized structural model for ICI-118551-bound b2AR
is therefore closer to the starting b2AR conformation com-
pared to the agonist-stabilized state. TM3 and TM6 rotate in
the same directions as the agonist-stabilized conformations.
However, TM5 rotates in the opposite direction, thereby
placing the three serines away from the binding pocket and
more toward the lipid bilayer. Similar to the agonists, ICI-
118551 has a protonated secondary amine group, which
makes a strong salt bridge (distance, 2.8 A˚) with D1133.32 on
TM3. ICI-118551 also has a hydroxyl group attached to the
main carbon chain. However unlike norepinephrine, the hy-
droxyl group is not located at the b-position and placed
further away from the aromatic group. In our predicted
structure, the hydroxyl group of ICI-118551 forms a hydro-
FIGURE 7 Predicted binding site of salbutamol in the optimized b2AR
conformation. The residues within 5 A˚ of the ligand are shown in gray. The
residues having strong interaction with the ligand are in green.
FIGURE 8 Predicted binding site of ICI-118551 in the optimized b2AR
conformation. The residues within 5 A˚ of the ligand are shown in gray. The
residues having strong interaction with the ligand are in green.
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gen-bond network with two residues on TM6, N2936.55
(distance, 2.9 A˚) and H2966.58 (distance, 3.1 A˚). We propose
that these two hydrogen bonds with the ligand stabilize the
receptor in an inactive state. The bulky aromatic group of ICI-
118551 strongly interacts with the aromatic residues on TM6,
F2896.51 and F2906.52. Unlike the agonists, the aromatic
group of ICI-118551 does not have any hydroxyl group and
forms no polar contact with the serine residues on TM5. The
two methyl groups present near the tertiary amine of ICI-
118551 show favorable hydrophobic contacts with Y1995.38
on TM5. Y1995.38 has been shown to interact with the an-
tagonist carazolol using ﬂuorescence quenching studies (56).
The methyl groups on ICI-118551 also interact favorably
with T1103.29 and V1143.33 on TM3.
Helical rotation similarities and differences
among agonists and inverse agonist
The predicted ligand-stabilized receptor models exhibit
similarities with and differences from one another, as evi-
denced by the ﬂuorescence experiments. Thus, for the agonist
and the three partial agonists studied here, our predictions
show a clockwise rotation of TM3 and counterclockwise
rotations of TM5 and TM6, when viewed from the extra-
cellular side. For the inverse agonist, TM5 prefers a clock-
wise rotation. It should be noted that the directions of the
rotations are relative to the starting structure, which is the
apoprotein structure in this case. In both bovine rhodopsin
and b2AR, strong experimental evidence (7,26) points to-
ward a counterclockwise rotation of TM6, which is in
agreement with our observations. TM3, TM5, and TM6 show
rotational changes for norepinephrine, dopamine, and sal-
butamol, whereas only TM3 and TM5 show rotational
changes for catechol-bound b2AR. The above observations
indicate that the driving force for TM5 rotation is to bring all
the three serines inside the ligand-binding cavity to form HBs
with the ligand -OH groups. Thus, the TM5 movement is
common to all the four agonists, although to different extents.
The inverse agonist ICI-118551 does not form any HB with
the TM5 serines and hence does not cause any signiﬁcant
rotation of TM5. Fig. 9 shows the different steps in norepi-
nephrine-induced helical rotations. The shape of the binding
pocket is represented by the blue surface. The movement of
TM5 and subsequent reshaping of the binding cavity as
shown in Fig. 9 b leads to pulling of the ligand closer to TM5.
Therefore, TM3 and TM6 undergo conformational changes
to move closer to the ligand to optimize the distances between
the protonated amine and b-OH groups. This leads to
breaking of the ionic lock between TM3 and TM6. For the
weak partial agonist catechol, the only major movement
observed is in TM5, which improves the hydrogen-bond
interactions between the serines and catechol OH groups;
there is very little rotational movement of TM6.
Interhelical hydrogen bond differences among
catechol agonists and noncatechol agonists
The structural differences among the various adrenergic ag-
onists are reﬂected in the receptor conformations stabilized
by these ligands. The receptor conformations differ in 1), the
position of the ligand inside the binding cavity; and 2),
the interhelical HB contacts. Norepinephrine and dopamine,
the catecholamine agonists, occupy almost the same position
inside the binding cavity, whereas salbutamol (a noncatechol
partial agonist) is shifted more toward TM4. In addition,
norepinephrine and dopamine reﬂect a similar pattern of in-
terhelical HB contacts, which is different from that of sal-
butamol. The HB between T1183.37 and T1644.56 is broken
by salbutamol, but is preserved in the norepinephrine- and
dopamine-bound structures. In the apoprotein state, the side-
chain sulfur of C1253.44 on TM3 hydrogen bonds with the
backbone oxygen of V2185.57 at the intracellular end of TM5.
This HB is broken by both norepinephrine and dopamine,
but preserved by salbutamol. These two examples indicate
that the catecholamine agonists follow a common trend in
breaking or preserving the same interhelical HBs. Moreover,
all of the interhelical HBs that distinguish the salbutamol-
bound conformation from the norepinephrine- or dopamine-
bound conformations involve TM3. We ﬁnd that the rotation
of TM3 in the case of salbutamol is 50% less compared to
those in norepinephrine and dopamine, which accounts for
the differences among the interhelical HBs involving TM3.
This is because TM5 does not have to rotate much to make
HBs with the longer hydroxyl groups of salbutamol. On the
other hand, the HB contacts that distinguish the full agonist
norepinephrine from the other agonists all involve TM6. One
of them is the HB between W2866.48 and M2155.54, which is
only present in the norepinephrine-bound state. In the apo-
protein state, N3187.45 hydrogen-bonds with the backbone
sulfur of C2856.47. This HB is broken by norepinephrine and
FIGURE 9 Different steps in the receptor conforma-
tional change induced by norepinephrine. The shape of
the binding cavity is represented by the blue surface. Note
that in b, the shape of the binding cavity is shifted toward
TM5, which makes TM3 and TM6 rotate.
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salbutamol, and not by dopamine. In the case of norepi-
nephrine, the rotation of TM6 is 15 more than the rotation
for dopamine and salbutamol, which explains the differences
among the TM6 contacts.
Conformational switches
It has been proposed in the literature that the active states of
GPCRs are characterized by breaking and making confor-
mational switches (1,6). These conformational switches are
turned on by ligand binding and allow the receptor to change
conformation toward activation. Two such switches identi-
ﬁed in rhodopsin and b2AR are the ionic lock between TM3
and TM6 and the rotamer toggle switch on TM6 (discussed in
the Introduction) (6,13,33). All the ligands engage different
switches or combinations of switches, and this has been ex-
perimentally demonstrated for ligands of different efﬁcacy
for b2AR. The strong agonists, such as norepinephrine, turn
on both ionic lock and rotamer toggle switches, partial ago-
nists turn on one or the other switch, whereas inverse agonists
and antagonists do not engage any of these switches (6). We
have investigated the status of these two conformational
switches in our ligand-stabilized receptor conformations.
Ionic lock between TM3 and TM6
For the ionic lock, we compared the energy of the confor-
mations with and without the ionic lock. For the apoprotein
state, the structure with the ionic lock is 5 kcal/mol more
stable than the conformation without the ionic lock. This
shows that the ionic lock is maintained in the apoprotein
state. In the predicted models, norepinephrine, dopamine,
and salbutamol stabilize helical rotations where the ionic lock
is broken, whereas catechol does not break the ionic lock.
Although norepinephrine, dopamine, and salbutamol induce
conformational changes in both TM3 and TM6, catechol
leads to a conformational change only in TM3. It follows that
simultaneous movements of both TM3 and TM6 are required
for breaking the ionic lock. This is in agreement with the
experiments reported in Yao et al. (6).
Rotamer toggle switch on TM6
We also investigated the status of the rotamer toggle switch in
our predicted structural models. In the various GPCRs
studied so far, the tryptophan in the WxP motif on TM6 is
found to toggle its rotamer in response to conformational
changes in its environment. The rotamer of W2866.48 is de-
termined by two factors, 1), movement of TM6, and 2), po-
sition of the ligand aromatic moiety inside the binding cavity.
The interaction between the ligand and W2866.48 is mediated
by F2906.52, which is located between the ligand and the
W2866.48 rotamer (Supplementary Material, Fig. S5). Both
norepinephrine and dopamine engage the rotamer toggle
switch because the aromatic ring is close to theWxPmotif on
TM6. On ligand binding and subsequent TM6 movement,
F2906.52 alters its rotamer conformation in order to maximize
the pi-pi interaction with the ligand. Conformational change
in F2906.52 rotamer leads to the toggling of the W2866.48
rotamer, which is located right below F2906.52 and interacts
with the F2906.52 rotamer. In case of salbutamol, the aromatic
ring of the ligand is located further away from TM6. As a
result, the interaction between salbutamol and the TM6 res-
idues is too weak to induce a rotamer toggling. The very
weak agonist catechol binds very close to the WxP motif of
TM6 and thereby engages the rotamer toggle switch without
causing any conformational change to TM6.
Comparison of the binding sites of
norepinephrine, dopamine, salbutamol,
and catechol
Fig. 10 a shows the binding sites for all four ligands super-
imposed on one another. Although the aromatic rings of
norepinephrine and dopamine occupy similar locations, the
aromatic ring of salbutamol is shifted more toward TM4.
Catechol binds deeper into the binding pocket compared to
the other three ligands. Fluorescence lifetime measurements
(11) indicate that catechol competes with both norepineph-
rine and dopamine for binding to b2AR, and does not com-
pete with salbutamol. A part of the catechol binding site
FIGURE 10 Comparison among the binding
sites of norepinephrine, dopamine, salbutamol,
and catechol. (a) Superposition of all four
binding sites. (b) Orientations of norepineph-
rine, salbutamol, and catechol.
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overlaps with both norepinephrine and dopamine, but not
with salbutamol (Fig. 10 b). As discussed earlier, the binding
site of salbutamol is slightly different compared to norepi-
nephrine and dopamine. The different orientation of the
aromatic ring of salbutamol is due to the presence of the
-CH2OH group on the aromatic ring, which pushes the aro-
matic part of salbutamol more toward TM4 to avoid steric
clashes between the CH2OH group and the TM5 residues.
Therefore, in our models, catechol shares a common binding
site with both norepinephrine and dopamine, but not with
salbutamol. This explains why catechol competes with nor-
epinephrine for binding, and not with salbutamol (11).
Analysis of the residues in the binding cavities indicates
that there are several common residues that interact with the
ligands norepinephrine, dopamine, and salbutamol. These in-
clude D1133.32, W1093.28, and V1173.36 on TM3; S2035.42,
S2045.43, and S2075.46 on TM5; N2936.55 and H2966.58 on
TM6; and L3117.38 on TM7. D1133.32 (conserved among all
biogenic amine receptors) forms a salt bridge with the pro-
tonated amine nitrogen of the ligands (18). N2936.55 (present
only in b2AR) on TM6 forms a hydrogen bond with the b-OH
group of norepinephrine. The hydrogen bond interaction of
N2936.55 with norepinephrine depends on the position of the
b-OH group at the stereocenter. Among the two isomers of
norepinephrine, the () isomer shows a better binding afﬁnity
compared to the (1) isomer, because only the () isomer is
capable of forming a hydrogen bond with N2936.55. This ac-
counts for the stereospeciﬁcity of the () norepinephrine in
binding to b2AR (55). Among the three serines on TM5 that
interact with the ligands, the interaction of S2075.46 is the
strongest. Norepinephrine shows equal interaction with the
other two serines, S2035.42 and S2045.43, whereas for dopa-
mine the interaction with S2035.42 is weaker than that with
S2045.43. Mutation results show that S207A has a larger effect
on norepinephrine binding compared to S204A (54), whereas
for dopamine, the effect of mutation on S2045.43 is higher than
that on S2035.42 (54). This is in agreement with our predicted
models. In a different study, it was shown that the S204A
mutation has a larger effect on salbutamol binding compared
to S207A (57). In ourmodel, the distance between the S2045.43
side chain and the salbutamol meta-OH group is shorter
(3.4 A˚) compared to the distance between S2045.43 and the
norepinephrine para-OH group (4 A˚). The longer -CH2OH
group of salbutamol places the oxygen atom of the OH closer
to the S2045.43 side chain compared to the oxygen atom of
norepinephrine. This may explain why the S204A mutation
has a larger effect on salbutamol than does S207A,whereas the
opposite is true with norepinephrine.
Norepinephrine, dopamine, and salbutamol all interact
with W1093.28 on TM3. For dopamine, this interaction is 2.5
kcal/mol stronger compared to the other two ligands. Inter-
estingly, W1093.28 moves into the binding pocket as a result
of rotation of TM3. Besides D1133.32, the ligands also in-
teract with several hydrophobic residues on TM3, which
include V1143.33 and V1173.36. These residues form the base
of the binding cavity in b2AR. Among the three ligands, only
the strong agonist norepinephrine shows a favorable inter-
action with F2085.47 on TM5. Dopamine also interacts with
F2085.47, but the strength of this interaction is weaker com-
pared to norepinephrine, whereas salbutamol does not in-
teract with F2085.47. This residue is conserved among all
biogenic amine receptors and may help to distinguish the
binding mode of full agonists from that of the partial agonists.
Due to its small size, catechol binds deeper into the protein
cavity compared to the other three ligands. Unlike the other
three ligands, catechol does not show any interaction with
D1133.32 on TM3. One of the OH groups on catechol forms a
hydrogen bond with N2936.55 on TM6, and the other OH
group forms a hydrogen bond with S2075.46 on TM5. The
aromatic ring of catechol strongly interacts with the aromatic
cluster on TM6 comprising F2906.52 and W2866.48 and a few
hydrophobic residues such as I2946.56 and V2976.59.
Potential conformational switches
distinguishing full from partial agonists: role of
F2826.44 on TM6
F2826.44 is a highly conserved residue (conserved among the
biogenic amine receptors) in TM6 one turn below the tryp-
tophan of the WxP motif. Mutating F2826.44 to hydrophobic
residues such as alanine and leucine has been shown to
increase the constitutive activity of the b2AR (16). In our
apoprotein model, F2826.44 interacts with another aromatic
residue Y3267.53 on TM7, which is part of the GPCR con-
served NPxxY motif. This p-p aromatic interaction con-
tributes to the stability of the apoprotein conformation of the
receptor. Mutating F2826.44 to hydrophobic residues will
eliminate this interaction with Y3267.53 and result in consti-
tutive activity. Comparing the conformations of F2826.44 in
the different ligand optimized states, as shown in Fig. 11, we
ﬁnd that norepinephrine causes F2826.44 to move away from
Y3267.53 (distance increases from 6 A˚ to 7.6 A˚), whereas for
salbutamol, the distance between F2826.44 and Y3267.53 de-
creases to 4.3 A˚. In the case of dopamine, the distance
between these two residues is 6.9 A˚, and for catechol, the
distance does not change. Therefore, according to our pre-
dictions, the full agonist norepinephrine completely breaks
the contact between F2826.44 and Y3267.53, and the partial
agonist dopamine weakens this interaction. Salbutamol (the
noncatecholamine partial agonist) stabilizes the interaction
between these two residues. This could be tested out exper-
imentally to distinguish full agonists from partial agonists.
Role of F2085.47 on TM5 in mediating the rotamer
toggle switch on TM6
In our predicted ligand-bound conformations, F2085.47 on
TM5 shows a strong interaction with the bound agonists.
F2085.47 is conserved among the biogenic amine receptors. In
the apoprotein state, F2085.47 is initially outside the binding
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cavity, but it moves in once the ligand binds and causes a
conformational change to the receptor. The interaction be-
tween the agonists and F2085.47 is stronger by 1.4 kcal/mol
compared to the interaction with F2906.52. According to the
rotamer toggle switch model proposed in the literature,
F2906.52 directly interacts with the ligand and transmits a
conformational signal to theW2866.48 rotamer. In our ligand-
bound conformations, the F2085.47 rotamer is positioned
between the catechol ring and F2906.52 (Fig. 12) and shows a
strong interaction with both the ligand and F2906.52. There-
fore, F2085.47 is likely to play a role in the rotamer toggle
switch, possibly by mediating the conformational signal from
the agonist to F2906.52. This suggests a potential role of TM5
in rotamer toggling, in addition to the role of TM6.
A potential molecular switch for distinguishing
the role of the b-hydroxy group in
norepinephrine from that in dopamine
In the norepinephrine-bound conformation, toggling of the
W2866.48 rotamer places the imidazole nitrogen facing TM5.
This facilitates the formation of a hydrogen bond with
M2155.54 on TM5 (Fig. 12), which is partially conserved
among the adrenergic receptors. This hydrogen bond is not
present in any other agonist-stabilized structure. For the
partial agonists salbutamol and dopamine, the rotation of
TM6 is not sufﬁcient to bring theW2866.48 side chain close to
M2155.54 for the formation of the hydrogen bond. Norepi-
nephrine and dopamine turn on both the ionic lock and the
rotamer toggle switches, but they stabilize distinctly different
receptor conformations, as observed in the ﬂuorescence ex-
periments. Therefore the question arises whether there is a
third molecular switch that can distinguish the norepineph-
rine-bound structure from the dopamine-bound structure.
The possibility that the HB between W2866.48 and M2155.54
could potentially serve as this new molecular switch can be
veriﬁed experimentally.
Insight into GPCR activation
In the predicted receptor models, the conformational states
stabilized by each ligand for the same receptor are distinct
from one another. The ﬁve ligands studied here differ in the
rotation of TM5 and TM6. Fig. 13, a and b, shows the section
of the ligand-binding energy landscape for the inverse ago-
nist ICI-118551 and the full agonist norepinephrine, re-
spectively, for rotations of TM5 and TM6 keeping TM3 at a
ﬁxed angle. The location of the starting structural model and
the ﬁnal ligand-stabilized model for each ligand are shown in
Fig. 13. The ICI-118551-stabilized state is located close to
the initial state on the binding energy landscape. The agonist-
stabilized states are in the blue region in Fig. 13 a, showing
that the inverse agonist has favorable binding energies for
these receptor conformations as well. However, there is a
signiﬁcant energy barrier between the inverse-agonist- and
agonist-stabilized states, as shown in Fig. 13 a. This makes
the agonist-bound conformations inaccessible to the inverse
agonist. Examining the receptor structural models, we ﬁnd
that the energy barrier could arise due to a steric clash be-
tween F2085.47 on TM5 and the aromatic part of ICI-118551,
which restricts TM5 rotations. We propose that mutating
F2085.47 to alanine will reduce the inverse agonistic effect of
ICI-118551, thereby serving as a possible validation for this
structural model. As seen in Fig. 13 b, positive rotation an-
gles for TM6 are associated with unfavorable binding ener-
gies for both the agonist and the inverse agonist. The rest of
the binding energy landscape for norepinephrine (Fig. 13 b)
shows smaller energy barriers compared to the inverse ago-
nist landscape. The receptor states stabilized by all the lig-
ands are accessible from an agonist-bound state. The highest
FIGURE 11 Relative orientations of F282 and Y326 in the apoprotein and
ligand-bound structures. (a) Apoprotein conformation. (b) Norepinephrine-
stabilized state. (c) Salbutamol-stabilized state.
FIGURE 12 Location of F208 on TM5 in the binding pocket of norep-
inephrine, shown along with the WxP motif on TM6. Norepinephrine is
shown in pink.
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energy barrier in the norepinephrine landscape is ;5 times
lower compared to the highest barrier in the ICI-118551
landscape. The ﬂat energy landscape of norepinephrine (and
also the other agonists not shown) reﬂects the increased
conformational ﬂexibility of an agonist-bound receptor as
opposed to an inverse-agonist-bound receptor. These calcu-
lations provide a quantitative model for the intuitive protein
energy landscapes discussed by Kobilka and co-workers
(58).
Virtual ligand screening of ligand optimized
receptor conformations
To demonstrate the use of the ligand optimized receptor
conformation compared to the apoprotein conformation for
drug design, we carried out a VLS of 10,060 ligands on the
apoprotein and the norepinephrine-bound conformations. For
both receptor conformations, all the adrenergic ligands
scored among the top 40% after sorting by protein-ligand
interaction, as described in the Methods section. Fig. 12
shows the distribution of the adrenergic ligands in the sorted
ligand list for the apoprotein and the norepinephrine-bound
conformations. In Fig. 14, each datapoint represents the
probability of ﬁnding adrenergic ligands within a certain
percent-cutoff range. For example, the point corresponding
to the 15% cutoff represents the probability of ﬁnding adren-
ergic ligands between 12.5% and 17.5% cutoffs. For both
conformations, the distributions show a high concentration of
adrenergic ligands around a 10% cutoff. The norepinephrine-
bound conformation shows a sharper, narrower peak com-
pared to the apoprotein conformation, which indicates a
higher localization of adrenergic ligands toward lower per-
cent cutoffs for the norepinephrine-bound conformation.
Next, we compare the yield of adrenergic ligands in the two
conformations (Table 1). At low percent cutoffs, the norepi-
nephrine-bound conformation shows consistently higher
yields compared to the apoprotein conformation. For a ﬁlter
cutoff of 10%, which is a common percent cutoff in com-
mercial drug screening, the apoprotein conformation shows a
26% yield of adrenergic ligands, whereas for the norepi-
nephrine-bound conformation, the yield is 36%. Therefore,
using the norepinephrine-bound conformation improves the
overall yield by 38% compared to apoprotein. Above 25%,
the yields for both the conformations become comparable to
one another.
CONCLUSION
We applied the LITiCon procedure for examining the per-
turbations caused by ligand binding to GPCRs, by a sys-
tematic spanning of helical rotational orientations. The
method was tested on human b2AR, for which experimental
information on the activation kinetics and conformational
changes is available. Starting from a model of the b2AR re-
ceptor, predicted using MembStruk4.0, and ligand docking,
using Glide, we predicted the binding sites for ﬁve adrenergic
ligands: norepinephrine (full agonist), salbutamol (partial
agonist), dopamine (weak partial agonist), catechol (very
weak partial agonist), and ICI-118551 (inverse agonist). We
calculated the changes in rotational orientation induced by
FIGURE 13 Binding energy land-
scapes (as a function of TM5 versus
TM6 rotation) for two adrenergic lig-
ands. (a) Inverse agonist ICI-118551.
(b) Full agonist norepinephrine. The red
regions represent unfavorable binding
energies and the blue regions represent
favorable binding energies. The various
ligand-stabilized states are marked by
dark circles. The white circles represent
the possible inverse agonist stabilized
states.
FIGURE 14 Distribution of adrenergic ligands in the sorted ligand list ob-
tained fromVLS. The distribution curves are shown after Gaussian smoothing
and noise removal. The total number of ligands in the test database was 10,060.
The optimum enrichment obtained corresponded to a 10% cutoff.
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ligand binding for each helical domain for the ﬁve ligands.
The binding energy surfaces for various helical rotational
orientations were calculated. Experimentally, the different
ligand-stabilized conformations are characterized by break-
ing of the ionic lock between R1313.50 on TM3 and E2686.30
on TM6 and the rotamer toggle switch of W2866.48 on TM6.
Norepinephrine and dopamine engage both of these switches,
but salbutamol only breaks the ionic lock, and catechol only
activates the rotamer toggle switch. These results are in
agreement with the predictions made using our method. We
also investigated the binding cavity positions of the ﬁve
ligands and described the similarities and differences among
them. Norepinephrine and dopamine occupy the same posi-
tion inside the binding cavity, and the binding site of salbu-
tamol is shifted toward TM4 and away from TM6. The
catechol binding site overlaps with those of norepinephrine
and dopamine, but not with salbutamol. This is in agreement
with the competition studies involving catechol, norepi-
nephrine, and salbutamol. The inverse agonist ICI-118551
binds deep into the binding pocket and stabilizes the receptor
in a conformation close to the starting structural model. The
inverse agonist does not form any HBs with the serines on
TM5, but forms a HB with H2966.58 and N2936.55 on TM6.
The predictions made for the agonists bring out the similar-
ities and differences between the binding sites of the ligands,
in full agreement with the mutation experiments.
One of the important predictions of this method is a po-
tential conformational switch that distinguishes catechol
agonists from a noncatechol agonist like salbutamol. We ﬁnd
that the full agonist norepinephrine breaks the contact be-
tween F2826.44 on TM6 and Y3267.53 on TM7, whereas the
partial agonist salbutamol stabilizes this interaction. This can
be tested experimentally and could potentially serve as a
distinguishing feature among full and partial agonists. An-
other prediction is that a conformational switch deﬁnes the
role of the b-hydroxyl group in norepinephrine that makes it
a stronger agonist than dopamine. The interhelical HB be-
tween W2866.48 and M2155.54 is formed upon activation by
norepinephrine, whereas this is not present for the dopamine-
stabilized state. This could potentially serve as a new mo-
lecular switch, which can be veriﬁed experimentally.
The binding energy surface for the inverse-agonist-bound
b2AR shows that the agonist-stabilized conformations are
inaccessible to the inverse agonist, because it is separated
from them by a large energy barrier. However, the binding
energy surface of the agonist-bound b2AR shows that other
conformations are accessible for the agonist-bound state. The
highest energy barrier in the norepinephrine landscape is
about ﬁve times lower than the highest barrier in the ICI-
118551 landscape, thus showing that the agonist-bound con-
formation is ﬂexible. These calculations provide a quantitative
basis for the existing intuitive models for GPCR activation
(58).
Since each ligand stabilizes a slightly different receptor
conformation, this computational method is very useful for
drug design. We have shown that VLS of large ligand li-
braries leads to a substantial enrichment in the hit rate at 10%
cutoff for the ligand-stabilized conformations. LITiCon can
be applied to any starting structure, be it a crystal structure, a
homology model of the receptor with the ligand docked, or
any other model. Moreover, the LITiCon method can be used
to derive models that can guide experiments in the study of
activation processes in class A GPCRs using biophysical
techniques. The method does not take into account the allo-
steric conformational changes that occur in the ligand-bound
receptor. However, using a ligand-stabilized receptor con-
formation from this study, one could perform MD simula-
tions for mapping the initial events leading to allosteric
conformational changes.
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